HYFT — MindWalk Holdings Corp.

Summary of HYFT (MindWalk) Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $4.1 million, a 54% increase year-over-year and 30% sequentially, marking a record quarterly revenue for continuing operations.
• Gross Profit: $2.7 million, representing a 94% year-over-year increase and a gross margin of 65%, up from 51% in the same period last year.
• Operating Expenses: $5.4 million, slightly higher than the previous year, attributed to increased R&D and sales/marketing investments.
• Operating Loss: Improved to $2.8 million from $4.1 million year-over-year.
• Net Loss: $3.2 million, compared to $2.6 million in the prior year, impacted by a divestiture-related charge.
• Cash Position: Ended the quarter with $16.5 million in cash, bolstered by the divestiture of noncore operations.

2. Strategic Updates and Business Highlights

• Divestiture: Sold noncore wet lab operations in the Netherlands for approximately $14.3 million, strengthening the balance sheet and aligning with the BioNative AI strategy.
• Corporate Rebranding: Transitioned to MindWalk, with a unified identity and the NASDAQ ticker HYFT, emphasizing the focus on AI-driven biologics.
• Product Development: Advanced programs in GLP1 receptor agonists and dengue vaccine initiatives using the proprietary HYFT patterns and LensAI technology.
• New Leadership: Appointed Scott Areglado as CFO and Dr. Thomas Lynch as Chief Business Officer to enhance financial strategy and commercial capabilities.

3. Forward Guidance and Outlook

• Gross Margin: Expected to maintain the mid-60s percentage range, with potential for further increases as scalable programs expand.
• Investment Focus: Plans to use proceeds from the divestiture to enhance the LensAI platform, commercial initiatives, and R&D for internal programs.
• Cayman Islands Portfolio Structure: Working on establishing a segregated portfolio structure to protect IP and allow for direct investment in specific AI-driven assets, which could attract capital without diluting existing shareholders.

4. Bad News, Challenges, or Points of Concern

• Net Loss: Increased net loss compared to the previous year, primarily due to divestiture impacts and tax expenses, which could raise concerns about profitability.
• Operating Expenses: Continued rise in operating expenses may pressure future profitability if not managed carefully.
• Market Competition: The rapid growth of AI in biotech could intensify competition, making it crucial for MindWalk to maintain its technological edge and market position.

5. Notable Q&A Insights

• Segregated Portfolio Structure: Management emphasized that this structure allows for asset-level investments without diluting equity in MindWalk Holdings Corp, addressing investor concerns about potential dilution.
• Future Capital Needs: Clarified that while a $30 million ATM facility is available, it is not an immediate focus, and the company prefers to leverage existing cash and potential partnerships to fund growth.
• Sales and Business Development: The new Chief Business Officer's mandate includes building a unified sales team and optimizing the SaaS model, which is critical for future revenue growth.

Overall, MindWalk demonstrated strong financial performance in Q2 2026, with significant revenue growth and improved margins, while also outlining strategic initiatives to enhance its position in the AI-driven biotech market. However, challenges remain in managing expenses and navigating competitive pressures.